Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

Nina S. Kjellson, a director at Tyra Biosciences , Inc. (NASDAQ:TYRA), recently sold shares of the company's common stock totaling $74,323. The timing of this insider sale comes as the stock trades ...

while being agnostic for the FGFR3 gatekeeper mutations. TYRA-300 is expected to be evaluated in three Phase 2 studies: SURF302 for IR NMIBC, BEACH301 for pediatric achondroplasia and SURF301 for ...

These results demonstrate that FOXG1 suppresses Fgfr3 gene expression and the MAPK/ERK pathway, and loss of Foxg1 results in an enhancement of this pro-gliogenic pathway. The decline in nuclear FOXG1 ...

The shares of Dixon Technologies (India) Ltd were trading at ₹15,551.85 down by 2007.60 or 11.43 percent on the NSE today at 10.20 am. Dixon Technologies (India) Ltd reported a consolidated net ...

3M reported Q4 adjusted sales of $5.808 billion, up 2.22% YoY, beating consensus expectations of $5.781 billion. Adjusted organic sales grew 2.1% despite a 70-basis-point headwind from portfolio ...

Their findings, published in Nature Aging, describe a never-before-seen link between the two most accepted explanations: random genetic mutations and predictable epigenetic modifications.

Taiwanese expect GDP growth this year to approach 3 percent and the TAIEX to rally above 24,000 points, as major local technology firms benefit further from artificial intelligence (AI) applications, ...

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

Inflation continues to erode purchasing power, and recent volatility highlights the uncertainty in inflation trends. Despite this, long-term investors can still find opportunities. In an ...